Evidence map›Paper›PMID 30565048›Full record

ArticleFolia microbiologica2019

Secondary metabolites produced by Microbacterium sp. LGMB471 with antifungal activity against the phytopathogen Phyllosticta citricarpa.

Daiani Cristina Savi, Khaled A Shaaban, Francielly M W Gos, Jon S Thorson, Chirlei Glienke, Jürgen Rohr

Open access · greenAbstract read
In one paragraph

Article in Folia microbiologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Bio-priming with a consortium ofFrontiers in microbiology · 2022
    Article
  7. Bioactive antifungal metabolites produced by Streptomyces amritsarensis V31 help to control diverse phytopathogenic fungi.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Daiani Cristina SaviDepartment of Genetics, Federal University of Paraná, Box 19031, Curitiba, PR, 81531-990, Brazil. daianicsavi@gmail.com.ORCID http://orcid.org/0000-0003-4794-2823
Khaled A ShaabanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA.
Francielly M W GosDepartment of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.
Jon S ThorsonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA.
Chirlei GlienkeDepartment of Genetics, Federal University of Paraná, Box 19031, Curitiba, PR, 81531-990, Brazil. ch.glienke@gmail.com.
Jürgen RohrDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA. jrohr2@email.uky.edu.
University of Kentucky · USUniversidade Federal do Paraná · BR

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTSR01CA091901 · NCI · UNIVERSITY OF KENTUCKY · PI ROHR, JURGEN T · 2001 to 2017
$3.6M
Platform technologies for understanding and exploiting methylationR01GM115261 · NIGMS · UNIVERSITY OF KENTUCKY · PI PHILLIPS, GEORGE NEAL, THORSON, JON SCOTT · 2016 to 2019
$2.2M
Exploring Post-Type II PKS Frame ModificationsR01GM105977 · NIGMS · UNIVERSITY OF KENTUCKY · PI ROHR, JURGEN T · 2014 to 2017
$1.1M
Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico 486016/2011-0Funda??o Arauc?ria 441/2012 ? 23510National Institutes of Health CA 91091National Institutes of Health GM 105977National Institutes of Health R01 GM115261NCATS NIH HHS UL1 TR001998NCI NIH HHS R01 CA091901NIGMS NIH HHS R01 GM105977NIGMS NIH HHS R01 GM115261
6 · The paper itself

Abstract

The citrus black spot (CBS), caused by Phyllosticta citricarpa, is one of the most important citrus diseases in subtropical regions of Africa, Asia, Oceania, and the Americas, and fruits with CBS lesions are still subject to quarantine regulations in the European Union. Despite the high application of fungicides, the disease remains present in the citrus crops of Central and South America. In order to find alternatives to help control CBS and reduce the use of fungicides, we explored the antifungal potential of endophytic actinomycetes isolated from the Brazilian medicinal plant Vochysia divergens found in the Pantanal biome. Two different culture media and temperatures were selected to identify the most efficient conditions for the production of active secondary metabolites. The metabolites produced by strain Microbacterium sp. LGMB471 cultured in SG medium at 36 °C considerably inhibited the development of P. citricarpa. Three isoflavones and five diketopiperazines were identified, and the compounds 7-O-β-D-glucosyl-genistein and 7-O-β-D-glucosyl-daidzein showed high activity against P. citricarpa, with the MIC of 33 μg/mL and inhibited the production of asexual spores of P. citricarpa on leaves and citrus fruits. Compounds that inhibit conidia formation may be a promising alternative to reduce the use of fungicides in the control of CBS lesions, especially in regions where sexual reproduction does not occur, as in the USA. Our data suggest the use of Microbacterium sp. LGMB471 or its metabolites as an ecological alternative to be used in association with the fungicides for the control of CBS disease.

Indexed as

ActinomycetalesAscomycotaAsiaBrazilCitrusCulture MediaDiketopiperazinesFungicides, IndustrialIsoflavonesMicrobial Sensitivity TestsPlant DiseasesPlant LeavesSecondary MetabolismSpores, FungalUnited StatesCulture MediaDiketopiperazinesFungicides, IndustrialIsoflavones

Identifiers

PMID30565048
PMCPMC6531336
OpenAlexW2905407492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.